In addition, many of these patients had EGFR amplifications, even in cancers that are not typically driven by EGFR. The existing detailed molecular analyses of EGFR-mutant lung cancers in the African population are insufficient to provide insight as to potentially increased cancer risk that may be associated with this allele, which is classified as ‘likely benign’ in ClinVar42. This evidence concerns the gene EGFR and lung cancer.